Mivelsiran

DB19003InvestigationalGene Therapies

Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).

Code names
ALN-APP

Resolves to

Compound
UNII39CFL75KXHCAS2572991-83-2

What you can answer from here — as of April 23, 2025

3Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Mivelsiran, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In